泰州迈博太科药业有限公司于2015年入驻泰州市中国医药城，注册资本2000万美元。公司主要从事单抗药物生产，投资总额2亿美元，拟建厂房面积3万余平方，建设符合GMP标准的国际先进的抗体药物制备体系，以期打造国内抗体药物生产高地。迈博太科药业由上海张江生物技术有限公司（抗体药物与靶向治疗国家重点实验室）抗体研发团队提供一站式平台服务，致力于实现一系列重量级国家创新抗体药物的产业化。现有品种：治疗结直肠癌的重组抗EGFR人鼠嵌合单克隆抗体，治疗银屑病的重组人LFA3-抗体融合蛋白等。

Taizhou Mabtech Pharmaceutical Co., Ltd. joined the China Medical City （CMC） in 2015 with registered capital of USD 20 million, expanding a national highland for monoclonal antibody medicine manufacturing by establishing internationally advanced antibody medicine manufacture system with adopted cGMP standards, with a total investment of USD 200 million. Supported by the one-stop platform for therapeutic mAb medicine development provided by ZJ-Bio R****D Team （State Key Laboratory of Antibody Medicine an d Targeted Therapy）, Taizhou Mabtech Pharmaceutics Co., Ltd is dedicated to industrialization of a series of blockbuster innovative antibody drugs. Existing varieties: recombinant anti-EGFR human/mouse-chimeric monoclonal antibody for the treatment of colorectal cancer, recombinant human LFA3-antibody fusion protein for the treatment of psoriasis , et al.

视 频 资 料
http://www.tz2100.com/news/dqxw/gx/2015/4/9/1428544031298.shtml